Private Health Insurance In China: Keeping Up With The Evolving Payor System
The global pharmaceutical industry faces challenges in tapping into China’s booming health care market; coverage under public insurance is still very limited and what patients can afford to spend out-of-pocket is still inadequate for high-cost innovative medicines. Can private health insurance close the gap?
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.